Labcorp Holdings Inc. Q4 2025 Earnings Call Summary

Core Insights - The company experienced a 7% increase in top-line revenue and a 13% growth in adjusted EPS in 2025, driven by enhanced health system partnerships contributing over $1 billion in revenue over three years [1] Revenue Growth - Esoteric and specialty testing achieved double-digit growth, acting as a high-margin engine that captures broader routine testing volume once physicians adopt Labcorp for complex diagnostics [1] Genetic Testing Expansion - The integration of Invitae has expanded genetic testing capabilities, with management viewing it as a fully embedded component of their specialty portfolio, growing 2-3 times faster than the market [1] Central Laboratory Strength - Central Laboratory strength is attributed to high utilization in oncology, neurology, and cardiometabolic clinical trials, supported by a global footprint capable of standardized testing across 100 countries [1] Operational Efficiency - Operational efficiency is being enhanced through AI-powered solutions in pathology and microbiology, along with the implementation of Roche's fully automated mass spectrometry solution [1] Strategic Decisions - Early Development (ED) faced challenges, leading to a strategic decision to streamline the business by $50 million in annual revenue to improve utilization and segment profitability [1]